Laura Sim-Selley - Publications

Pharmacology & Toxicology Virginia Commonwealth University, Richmond, VA, United States 
Neuroscience Biology, Pharmacology

29 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2018 Kota D, Alajaji M, Bagdas D, Selley DE, Sim-Selley LJ, Imad Damaj M. Early adolescent nicotine exposure affects later-life hippocampal mu-opioid receptors activity and morphine reward but not physical dependence in male mice. Pharmacology, Biochemistry, and Behavior. PMID 30125591 DOI: 10.1016/J.Pbb.2018.08.006  0.331
2018 Sim-Selley LJ, Wilkerson JL, Burston JJ, Hauser KF, McLane V, Welch SP, Lichtman AH, Selley DE. Differential Tolerance to FTY720-induced Antinociception in Acute Thermal and Nerve Injury Mouse Pain Models: Role of S1P Receptor Adaptation. The Journal of Pharmacology and Experimental Therapeutics. PMID 29945931 DOI: 10.1124/Jpet.118.248260  0.312
2017 Lazenka MF, Kang M, De DD, Selley DE, Sim-Selley LJ. Δ(9)-Tetrahydrocannabinol Experience Influences ΔFosB and Downstream Gene Expression in Prefrontal Cortex. Cannabis and Cannabinoid Research. 2: 224-234. PMID 29082320 DOI: 10.1089/can.2017.0022  0.31
2016 Hahn YK, Paris JJ, Lichtman AH, Hauser KF, Sim-Selley LJ, Selley DE, Knapp PE. Central HIV-1 Tat exposure elevates anxiety and fear conditioned responses of male mice concurrent with altered mu-opioid receptor-mediated G-protein activation and β-arrestin 2 activity in the forebrain. Neurobiology of Disease. PMID 26845176 DOI: 10.1016/J.Nbd.2016.01.014  0.306
2015 Lazenka MF, Tomarchio A, Lichtman AH, Greengard P, Flajolet M, Selley DE, Sim-Selley LJ. Role of dopamine type 1 receptors and DARPP-32 in Δ9-THC-mediated induction of ΔFosB in the mouse forebrain. The Journal of Pharmacology and Experimental Therapeutics. PMID 26099530 DOI: 10.1124/Jpet.115.224428  0.328
2015 Ghosh S, Kinsey SG, Liu QS, Hruba L, McMahon LR, Grim TW, Merritt CR, Wise LE, Abdullah RA, Selley DE, Sim-Selley LJ, Cravatt BF, Lichtman AH. Full Fatty Acid Amide Hydrolase Inhibition Combined with Partial Monoacylglycerol Lipase Inhibition: Augmented and Sustained Antinociceptive Effects with Reduced Cannabimimetic Side Effects in Mice. The Journal of Pharmacology and Experimental Therapeutics. 354: 111-20. PMID 25998048 DOI: 10.1124/Jpet.115.222851  0.304
2014 Lazenka MF, David BG, Lichtman AH, Nestler EJ, Selley DE, Sim-Selley LJ. Delta FosB and AP-1-mediated transcription modulate cannabinoid CB₁ receptor signaling and desensitization in striatal and limbic brain regions. Biochemical Pharmacology. 91: 380-9. PMID 25093286 DOI: 10.1016/J.Bcp.2014.07.024  0.352
2014 Morgan DJ, Davis BJ, Kearn CS, Marcus D, Cook AJ, Wager-Miller J, Straiker A, Myoga MH, Karduck J, Leishman E, Sim-Selley LJ, Czyzyk TA, Bradshaw HB, Selley DE, Mackie K. Mutation of putative GRK phosphorylation sites in the cannabinoid receptor 1 (CB1R) confers resistance to cannabinoid tolerance and hypersensitivity to cannabinoids in mice. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 34: 5152-63. PMID 24719095 DOI: 10.1523/Jneurosci.3445-12.2014  0.309
2014 Lazenka MF, Selley DE, Sim-Selley LJ. ΔFosB induction correlates inversely with CB₁ receptor desensitization in a brain region-dependent manner following repeated Δ⁹-THC administration. Neuropharmacology. 77: 224-33. PMID 24090766 DOI: 10.1016/J.Neuropharm.2013.09.019  0.305
2012 Nguyen PT, Schmid CL, Raehal KM, Selley DE, Bohn LM, Sim-Selley LJ. β-arrestin2 regulates cannabinoid CB1 receptor signaling and adaptation in a central nervous system region-dependent manner. Biological Psychiatry. 71: 714-24. PMID 22264443 DOI: 10.1016/J.Biopsych.2011.11.027  0.337
2011 Sim-Selley LJ, Cassidy MP, Sparta A, Zachariou V, Nestler EJ, Selley DE. Effect of ΔFosB overexpression on opioid and cannabinoid receptor-mediated signaling in the nucleus accumbens. Neuropharmacology. 61: 1470-6. PMID 21907220 DOI: 10.1016/J.Neuropharm.2011.08.046  0.412
2011 Hoot MR, Sim-Selley LJ, Selley DE, Scoggins KL, Dewey WL. Chronic neuropathic pain in mice reduces μ-opioid receptor-mediated G-protein activity in the thalamus. Brain Research. 1406: 1-7. PMID 21762883 DOI: 10.1016/J.Brainres.2011.06.023  0.373
2011 Ramesh D, Ross GR, Schlosburg JE, Owens RA, Abdullah RA, Kinsey SG, Long JZ, Nomura DK, Sim-Selley LJ, Cravatt BF, Akbarali HI, Lichtman AH. Blockade of endocannabinoid hydrolytic enzymes attenuates precipitated opioid withdrawal symptoms in mice. The Journal of Pharmacology and Experimental Therapeutics. 339: 173-85. PMID 21719468 DOI: 10.1124/Jpet.111.181370  0.383
2010 Schlosburg JE, Blankman JL, Long JZ, Nomura DK, Pan B, Kinsey SG, Nguyen PT, Ramesh D, Booker L, Burston JJ, Thomas EA, Selley DE, Sim-Selley LJ, Liu QS, Lichtman AH, et al. Chronic monoacylglycerol lipase blockade causes functional antagonism of the endocannabinoid system. Nature Neuroscience. 13: 1113-9. PMID 20729846 DOI: 10.1038/Nn.2616  0.391
2010 Falenski KW, Thorpe AJ, Schlosburg JE, Cravatt BF, Abdullah RA, Smith TH, Selley DE, Lichtman AH, Sim-Selley LJ. FAAH-/- mice display differential tolerance, dependence, and cannabinoid receptor adaptation after delta 9-tetrahydrocannabinol and anandamide administration. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 35: 1775-87. PMID 20357755 DOI: 10.1038/Npp.2010.44  0.376
2008 Wiley JL, Kendler SH, Burston JJ, Howard DR, Selley DE, Sim-Selley LJ. Antipsychotic-induced alterations in CB1 receptor-mediated G-protein signaling and in vivo pharmacology in rats. Neuropharmacology. 55: 1183-90. PMID 18708079 DOI: 10.1016/J.Neuropharm.2008.07.026  0.311
2008 McKinney DL, Cassidy MP, Collier LM, Martin BR, Wiley JL, Selley DE, Sim-Selley LJ. Dose-related differences in the regional pattern of cannabinoid receptor adaptation and in vivo tolerance development to delta9-tetrahydrocannabinol. The Journal of Pharmacology and Experimental Therapeutics. 324: 664-73. PMID 17967938 DOI: 10.1124/Jpet.107.130328  0.36
2007 Smith PA, Selley DE, Sim-Selley LJ, Welch SP. Low dose combination of morphine and delta9-tetrahydrocannabinol circumvents antinociceptive tolerance and apparent desensitization of receptors. European Journal of Pharmacology. 571: 129-37. PMID 17603035 DOI: 10.1016/J.Ejphar.2007.06.001  0.401
2007 Stoller DC, Sim-Selley LJ, Smith FL. Role of kappa and delta opioid receptors in mediating morphine-induced antinociception in morphine-tolerant infant rats. Brain Research. 1142: 28-36. PMID 17300766 DOI: 10.1016/j.brainres.2007.01.028  0.33
2006 Paugh SW, Cassidy MP, He H, Milstien S, Sim-Selley LJ, Spiegel S, Selley DE. Sphingosine and its analog, the immunosuppressant 2-amino-2-(2-[4-octylphenyl]ethyl)-1,3-propanediol, interact with the CB1 cannabinoid receptor. Molecular Pharmacology. 70: 41-50. PMID 16571654 DOI: 10.1124/Mol.105.020552  0.31
2006 Zachariou V, Bolanos CA, Selley DE, Theobald D, Cassidy MP, Kelz MB, Shaw-Lutchman T, Berton O, Sim-Selley LJ, Dileone RJ, Kumar A, Nestler EJ. An essential role for DeltaFosB in the nucleus accumbens in morphine action. Nature Neuroscience. 9: 205-11. PMID 16415864 DOI: 10.1038/Nn1636  0.398
2004 Cichewicz DL, Cox ML, Welch SP, Selley DE, Sim-Selley LJ. Mu and delta opioid-stimulated [35S]GTP gamma S binding in brain and spinal cord of polyarthritic rats. European Journal of Pharmacology. 504: 33-8. PMID 15507218 DOI: 10.1016/J.Ejphar.2004.09.050  0.325
2004 Martin BR, Sim-Selley LJ, Selley DE. Signaling pathways involved in the development of cannabinoid tolerance. Trends in Pharmacological Sciences. 25: 325-30. PMID 15165748 DOI: 10.1016/J.Tips.2004.04.005  0.302
2003 Sim-Selley LJ. Regulation of cannabinoid CB1 receptors in the central nervous system by chronic cannabinoids. Critical Reviews in Neurobiology. 15: 91-119. PMID 14977366  0.382
2003 Zachariou V, Georgescu D, Sanchez N, Rahman Z, DiLeone R, Berton O, Neve RL, Sim-Selley LJ, Selley DE, Gold SJ, Nestler EJ. Essential role for RGS9 in opiate action. Proceedings of the National Academy of Sciences of the United States of America. 100: 13656-61. PMID 14595021 DOI: 10.1073/Pnas.2232594100  0.438
2003 Rahman Z, Schwarz J, Gold SJ, Zachariou V, Wein MN, Choi KH, Kovoor A, Chen CK, DiLeone RJ, Schwarz SC, Selley DE, Sim-Selley LJ, Barrot M, Luedtke RR, Self D, et al. RGS9 modulates dopamine signaling in the basal ganglia. Neuron. 38: 941-52. PMID 12818179 DOI: 10.1016/S0896-6273(03)00321-0  0.309
2003 Darmani NA, Sim-Selley LJ, Martin BR, Janoyan JJ, Crim JL, Parekh B, Breivogel CS. Antiemetic and motor-depressive actions of CP55,940: cannabinoid CB1 receptor characterization, distribution, and G-protein activation. European Journal of Pharmacology. 459: 83-95. PMID 12505537 DOI: 10.1016/S0014-2999(02)02815-7  0.301
2002 Sim-Selley LJ, Martin BR. Effect of chronic administration of R-(+)-[2,3-Dihydro-5-methyl-3-[(morpholinyl)methyl]pyrrolo[1,2,3-de]-1,4-benzoxazinyl]-(1-naphthalenyl)methanone mesylate (WIN55,212-2) or delta(9)-tetrahydrocannabinol on cannabinoid receptor adaptation in mice. The Journal of Pharmacology and Experimental Therapeutics. 303: 36-44. PMID 12235230 DOI: 10.1124/Jpet.102.035618  0.407
2002 Sim-Selley LJ, Sharpe AL, Vogt LJ, Brunk LK, Selley DE, Samson HH. Effect of ethanol self-administration on mu- and delta-opioid receptor-mediated G-protein activity. Alcoholism, Clinical and Experimental Research. 26: 688-94. PMID 12045478 DOI: 10.1111/J.1530-0277.2002.Tb02592.X  0.337
Show low-probability matches.